Rilzabrutinib is a medicine used to treat immune thrombocytopenia (ITP), a condition where the immune system destroys platelets and causes easy bleeding and bruising. It works by calming the immune signals that lead to platelets being destroyed. It's taken as a pill.
Every report comes from a Lived member, sent anonymously.
Have you tried Wayrilz (Rilzabrutinib) for Idiopathic Thrombocytopenic Purpura (ITP)?
Rilzabrutinib, sold as Wayrilz, is a prescription tablet for adults with immune thrombocytopenia (ITP), a condition in which the immune system destroys platelets. Platelets are the blood cells that plug small leaks in blood vessels, so when their count falls too low, the risk of bleeding rises, from minor bleeding to, less often, serious bleeding inside the body. Wayrilz was approved in the US in 2025 for adults whose ITP has continued past the newly diagnosed stage (persistent ITP) or has lasted a year or longer (chronic ITP), and who did not respond well enough to an earlier treatment. People in its main trial had typically already tried four earlier treatments, most often corticosteroids, and many had also tried thrombopoietin receptor agonists (medicines that push the bone marrow to make more platelets) or rituximab (an infused antibody medicine that reduces the immune cells that make antibodies). It has not been shown to be safe or effective in children.
In ITP, the immune system makes antibodies that stick to platelets. Immune cells in the spleen and liver then recognize those coated platelets and remove them from the blood far faster than the body can replace them. Rilzabrutinib blocks an enzyme called Bruton's tyrosine kinase (BTK), which acts as a switch inside several types of immune cells. Blocking it works on both sides of the problem: it dampens the B cells that produce the platelet-targeting antibodies, and it interferes with the signal that tells cells in the spleen and liver to swallow antibody-coated platelets. With fewer platelets being destroyed, the count can rise. It does not cure ITP; it is taken long term to keep the count up, and the label has no data on how long a response lasts after stopping.
Wayrilz comes as a 400 mg tablet taken twice a day, at about the same times each day. Swallow each tablet whole with a glass of water; do not cut, crush or chew it. It can be taken with or without food, and taking it with a meal can ease diarrhea, nausea or stomach pain. Before starting, the care team checks liver blood tests and, for anyone who could become pregnant, a pregnancy test. If a dose is missed, take it as soon as you remember on the same day, as long as it is at least 2 hours before the next scheduled dose; do not double up. If you take too much, call your prescriber right away.
Stomach and bowel symptoms are the most common. In the main trial, about a third of people had diarrhea and about one in five had nausea; headache and abdominal pain were also frequent. These were mild to moderate, and most people were able to keep taking the medicine with simple measures such as taking it with food. Joint aches, dizziness and cold-like symptoms were less common. Two serious risks need attention. Medicines that block BTK can make serious bacterial, viral or fungal infections more likely, and one person in the trial died of pneumonia. Contact your care team right away if you develop fever, chills or flu-like symptoms. Medicines in this class have also caused serious liver injury. Liver test rises seen with Wayrilz in ITP trials were mild to moderate, but tell your care team right away about stomach-area pain or discomfort, especially with dark or tea-colored urine, or yellowing of the skin or the whites of the eyes.
Rilzabrutinib needs stomach acid to dissolve well. Proton pump inhibitors (PPIs), a common type of heartburn and ulcer medicine, should be avoided while taking it. If you use an antacid or an H2 blocker (another type of heartburn medicine), take Wayrilz at least 2 hours before it. The liver breaks rilzabrutinib down through an enzyme called CYP3A, so medicines that slow or speed up this enzyme change how much of the drug stays in the body. Some raise rilzabrutinib levels and make side effects more likely, such as the antifungal fluconazole, the antibiotic erythromycin, verapamil (a blood pressure and heart rhythm medicine) and ritonavir (an HIV medicine). Others lower levels and can make Wayrilz less effective, such as rifampin and rifabutin (antibiotics used mainly for tuberculosis) and efavirenz (an HIV medicine). These combinations are generally avoided. If a short course of an antibiotic or antifungal that raises levels cannot be avoided, the prescriber may pause Wayrilz for those days. Grapefruit, starfruit and Seville oranges (often used in marmalade) also raise levels and should be avoided. Rilzabrutinib can in turn raise the levels of some other medicines, so share a full list, including over-the-counter medicines, vitamins and herbal supplements, with your prescriber and pharmacist. Wayrilz may harm a developing baby, based on animal studies. People who could become pregnant should use effective birth control during treatment and for 1 week after the last dose. Do not breastfeed during treatment or for at least 1 week after the last dose. It should be avoided in people with moderate or severe liver disease or severe kidney disease.
Wayrilz does not work for everyone, and response is measured by regular platelet counts. A typical adult count is about 150,000 to 450,000 platelets per microliter of blood. Below about 50,000, bleeding becomes more likely, even with everyday activities, and the main trial used 50,000 as its mark of a response. In that trial, about two in three people had a platelet response within the first 12 weeks (a count of at least 50,000, or at least 30,000 when that was double their starting count), compared with about one in three on a placebo, and the typical first response came after about five weeks. A steadier response, with the count staying at or above 50,000 for most of the last three months of the six-month study, was reached by about one in four people taking it and none taking placebo. People in the trial could stay on other ITP medicines, and fewer people on Wayrilz needed rescue treatment to quickly raise their count. Expect regular blood tests for platelets and liver function, especially in the first months. Any decision to stop or switch is made with the care team based on platelet counts and side effects.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Wayrilz (Rilzabrutinib), what you've noticed, or ask the community a question.